目的 研究福辛普利聯(lián)合羥苯磺酸鈣治療長期腹膜透析糖尿病腎病患者的臨床療效和安全性。方法 將67例長期進行腹膜透析的糖尿病腎病患者隨機分為對照組（36例）和治療組（31例），對照組口服福辛普利鈉片，10 mg/次，3次/d。治療組口服羥苯磺酸鈣分散片，0.5 g/次，3次/d，福辛普利的用法和用量同對照組。兩組患者均治療12周。治療后，比較兩組的臨床療效、腎功能改善情況、血糖控制情況。結(jié)果 治療后治療組和對照組的臨床總有效率分別為87.1%、63.9%，兩組比較差異有統(tǒng)計學意義（P＜0.05）。治療后，治療組腎功能改善更好，患者尿素氮、血清肌酐，24 h尿蛋白量下降程度較對照組更明顯，差異有統(tǒng)計學意義（P＜0.05）。治療后，治療組糖化血紅蛋白、空腹血糖和餐后2 h血糖均較對照組下降更加明顯，兩組比較差異有統(tǒng)計學意義（P＜0.05）。結(jié)論 福辛普利聯(lián)合羥苯磺酸鈣治療長期腹膜透析糖尿病腎病患者臨床療效較好，對患者腎功能的恢復有一定作用，值得臨床推廣。

Objective To investigate the clinical efficacy and safety of fosinopril combined with calcium dobesilate in treatment of long-term peritoneal dialysis patients with diabetic nephropathy. Methods Sixty-seven cases of long-term peritoneal dialysis patients with diabetic nephropathy were randomly divided into treatment (31 cases) and control (36 cases) groups. The patients in the control group were po administered with fosinopril 10 mg once, three times daily. The patients in the treatment group were po administered with calcium dobesilate 0.5 g once, three times daily. At the same time, fosinopril at the usage and dosage was used as same in the control group. Two groups were treated for 12 weeks. After the treatment, the clinical curative effects on improving renal function and controlling blood sugar in the two groups were compared. Results After the treatment, the total effective rates in the treatment and control groups were 87.1% and 63.9%. And there were significant differences between the two groups (P<0.05). After the treatment, the improvement of renal function in the treatment group was better. The urea nitrogen, serum creatinine, and decreased degree of 24 h urine protein were more significant than those in the control group, and the difference between the two groups was statistically significant (P<0.05). After the treatment, glycosylated hemoglobin, fasting blood glucose, and blood glucose in postprandial 2 h in the treatment group were down more obviously compared with the control group, the difference was statistically significant (P<0.05). Conclusion Fosinopril combined with calcium dobesilate has a good antihypertensive effect in the treatment of long-term peritoneal dialysis patients with diabetic nephropathy, and it has the certain effect for recovery of renal function, which is worth clinical promotion.